Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
55%(6 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
5
38%
Ph phase_1
8
62%

Phase Distribution

8

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
8(61.5%)
Phase 2Efficacy & side effects
5(38.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(11)
Terminated(2)

Detailed Status

Completed11
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
91.7%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (61.5%)
Phase 25 (38.5%)

Trials by Status

completed1185%
terminated18%
withdrawn18%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials
NCT03365947Phase 1

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Completed
NCT04439539Phase 2

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Completed
NCT04585789Phase 2

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Completed
NCT04129554Phase 2

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed
NCT03982186Phase 2

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Completed
NCT02662712Phase 1

A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

Completed
NCT03945539Phase 1

A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants

Completed
NCT03361956Phase 2

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Completed
NCT04474210Phase 1

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

Terminated
NCT04853524Phase 1

A Study of JNJ-56136379 in Healthy Participants

Withdrawn
NCT04208399Phase 1

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

Completed
NCT02933580Phase 1

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

Completed
NCT03111511Phase 1

A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13